The effect of age on the opportunity to receive cancer treatment

Habbous, Steven; Alibhai, Shabbir M.H.; Menjak, Ines B.; Förster, Katharina; Holloway, Claire; Darling, Gail

doi:10.1016/j.canep.2022.102271

Cited by 7 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These survival outcomes are relatively disappointing and shorter than commonly reported in studies of WBRT in unselected populations (all-comers irrespective of age) (14-16). It is well known that many octogenarians are poor candidates for standard anticancer treatment, including systemic drug therapy and surgery, and therefore unfavorable outcomes are not uncommon in this age-group (17)(18)(19). On the other hand, limited survival is not synonymous to limited benefit in terms of symptom palliation.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Independent Validation of a Risk Stratification Model in Octogenarian Patients Irradiated for Brain Metastases

Nieder

Dalhaug

2023

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: This study aimed at validation of a prognostic model, originally developed by Rades et al., in an age-restricted, particularly vulnerable subgroup of patients with brain metastases, because international variations in clinical practice and survival outcomes may impact on the performance of survival prediction tools. Materials and Methods: Retrospectively, data from a single institution were analyzed. The study included 50 patients managed with palliative whole-brain radiotherapy. The Rades et al. score was assigned and the resulting 3 prognostic strata compared. Results: The 3-month survival rates for the 3 strata were 0, 35 and 41%, respectively (p<0.001 pooled over all strata, log-rank test for Kaplan-Meier curves). However, the prognostic impact of extracranial metastases suggested by Rades et al., together with performance status and number of brain metastases in their study of 94 patients, was absent. In contrast, cancer type (better survival for breast and melanoma) and lack of steroid treatment were significant in the present study. Conclusion: The original Rades et al. score is a useful prognostic model in our validation database. However, additional factors appear to play a role and might therefore be considered when performing future large-scale studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Independent Validation of a Risk Stratification Model in Octogenarian Patients Irradiated for Brain Metastases

Nieder

Dalhaug

2023

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Studies have shown worse oncologic outcomes including undertreatment and worse cancer‐related mental health in the elderly 21 . With regard to prostate cancer, elderly patients are less likely to have a consultation with a surgeon, medical oncologist or radiation oncologist for a discussion of definitive treatment, compared to their younger counterparts 22 . This is despite evidence that well‐selected elderly patients have good oncological and functional outcomes from curative intent therapy 9,10,12,23 …”

Section: Discussionmentioning

confidence: 99%

“…21 With regard to prostate cancer, elderly patients are less likely to have a consultation with a surgeon, medical oncologist or radiation oncologist for a discussion of definitive treatment, compared to their younger counterparts. 22 This is despite evidence that wellselected elderly patients have good oncological and functional outcomes from curative intent therapy. 9,10,12,23 There are several studies reporting results of the treatment of localised prostate cancer in octogenarians.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of dose‐escalated IMRT and ADT in Octogenarians with prostate cancer

Armstrong

Shakespeare

2023

J Med Imag Rad Onc

View full text Add to dashboard Cite

IntroductionWe evaluated long‐term outcomes for octogenarians with localised prostate cancer treated using dose‐escalated image‐guided intensity‐modulated radiation therapy (IMRT) at our institution.MethodsThe charts of octogenarians treated for localised prostate cancer were retrospectively reviewed. Overall survival (OS), prostate cancer‐specific survival (PCaSS), toxicity rates and changes from baseline were collected.ResultsThe median follow‐up was 97 months. Of 107 eligible patients, 27.1% had intermediate‐risk and 72.9% had high‐risk localised prostate cancer. Median dose was 78Gy, and 97.2% received ADT. OS was 91.4% and 67.2% at 5 and 10 years. PCaSS was 98.0% and 88.7% at 5 and 10 years. In all, 39 (36.4%) of patients died, with the cause of death known in 30: in 26.7% of these patients, prostate cancer was the cause of death. Grade ≥ 2 late GI and GU toxicity was 0.9% and 24.3% respectively. In all, 11.2% and 22.4% of patients reported worsening of GI or GU function from baseline, and 13.1% and 21.5% reported improvement in GI and GU function compared to baseline.ConclusionSelected octogenarian patients with localised prostate cancer appear to benefit from radiation therapy and ADT. Despite excellent long‐term PCaSS, 26.7% of patients died of prostate cancer. Rates of GI and GU toxicity were acceptable, and deterioration of urinary and bowel function compared to baseline was just as common as improvement in function from baseline.

show abstract

“…Cancer is commonly a disease of the old, and median age at diagnosis considering all disease sites is 65 years according to U.S. Surveillance, Epidemiology and End Results (SEER) data [ 1 ]. Cancer registry data from Canada showed that 16% of cancer patients aged 45 to 99 years old were diagnosed at age 80 or older [ 2 ]. Several common cancers such as lung carcinomas, prostate cancer, and gastrointestinal carcinomas have a median age at presentation above 65 years old [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Presentation, Molecular Characteristics, Treatment, and Outcomes of Colorectal Cancer in Patients Older than 80 Years Old

Voutsadakis

2023

Medicina

View full text Add to dashboard Cite

Background: An increasing proportion of the population of patients with cancer presents at an advanced age, increasing the challenges of successful and well-tolerated treatments. In the older spectrum of the geriatric cancer patients, those older than 80 years old, challenges are even higher because of increasing comorbidities and decreasing organ function reserves. Methods: Studies regarding colorectal cancer presentation, treatment, and prognosis in patients older than 80 years old available in the literature were evaluated and were compiled within a narrative review. Molecular attributes of colorectal cancer in the subset of patients older than 80 years old in published genomic cohorts were also reviewed and were compared with similar attributes in younger patients. Results: Characteristics of colorectal cancer in octogenarians are in many aspects similar to younger patients, but patients older than 80 years old present more often with right colon cancers. Surgical treatment of colorectal cancer in selected patients over 80 years old is feasible and should be pursued. Adjuvant chemotherapy is under-utilized in this population. Although combination chemotherapy is in most cases not advisable, monotherapy with fluoropyrimidine derivatives is feasible and efficacious. Conclusions: Outcomes of colorectal cancer patients over the age of 80 years old may be optimized with a combination of standard treatments adjusted to the individual patient’s functional status and organ reserves. Increased support for the older age group during their colorectal cancer treatment modalities would improve oncologic outcomes with decreasing adverse outcomes of therapies.

show abstract

The effect of age on the opportunity to receive cancer treatment

Cited by 7 publications

References 43 publications

Prognostic Factors and Independent Validation of a Risk Stratification Model in Octogenarian Patients Irradiated for Brain Metastases

Prognostic Factors and Independent Validation of a Risk Stratification Model in Octogenarian Patients Irradiated for Brain Metastases

Outcomes of dose‐escalated IMRT and ADT in Octogenarians with prostate cancer

Presentation, Molecular Characteristics, Treatment, and Outcomes of Colorectal Cancer in Patients Older than 80 Years Old

Contact Info

Product

Resources

About